A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome Save

Date Added
July 16th, 2020
PRO Number
Pro00101619
Researcher
Bryan Garcia

List of Studies

Silhouette
Keywords
Coronavirus, COVID-19
Summary

The purpose of the study is to see if a medication called Ravulizumab (ULTOMIRIS) may reduce lung injury in people with pneumonia, acute lung injury (ALI), or acute respiratory distress syndrome (ARDS) that is associated with a COVID 19 infection. ULTOMIRIS is an investigational medication, meaning that it has not been approved by the FDA to treat these conditions. Participants will be randomly assigned (like flipping a coin) to receive the study medication or not receive the study medication. Participants who receive study drug will receive the study drug in their vein up to 4 times in a 2 week period. Study participation will last about 29 days.

Institution
MUSC
Recruitment Contact
April Rasberry
(843) 792-2375
rasberry@musc.edu

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19 Save

Date Added
June 2nd, 2020
PRO Number
Pro00099987
Researcher
Eric Meissner

List of Studies


Profiles_link
Keywords
Coronavirus, COVID-19
Summary

This is a study to see if an oral antiviral medication called AT-527 is an effective and safe treatment for COVID-19. AT-527 is an investigational medication, which means it has not been approved by the FDA to treat COVID-19 or any other disease. Patients who are hospitalized with COVID-19 and have moderate disease may be eligible for this study. Participants will be randomly assigned to receive active medication or placebo for 10 days. Study participation will last 2-6 weeks.

Institution
MUSC
Recruitment Contact
Max Lento
843-792-9697
lento@musc.edu

SCTR / MUSC COVID-19 Biorepository Save

Date Added
April 16th, 2020
PRO Number
Pro00098961
Researcher
Patrick Flume

List of Studies


Profiles_link
Keywords
Coronavirus, COVID-19, Infectious Diseases, Men's Health, Non-interventional, SARS-CoV-2, Women's Health
Summary

The Medical University of South Carolina (MUSC) is developing a COVID-19 biorepository which will contain blood, urine, and other bodily fluids along with relevant medical information from individuals evaluated, exposed to, or treated for COVID-19. To learn from this pandemic ,and to develop treatments and strategies to better prepare and avert future pandemics we must study the disease and its effects. The clinical specimens in the biorepository will be available for investigators to use for future research. Compensation is provided for participation in this project for eligible participants.

Institution
MUSC
Recruitment Contact
Ricardo Cantu
843-792-8894
coordinator@musc.edu

Rapid In-Home SARS-CoV-2 IgG Antibody Testing to Assess Community Level Immunity in Health Care Workers Working in High Risk Exposure Settings Save

Date Added
April 8th, 2020
PRO Number
Pro00099014
Researcher
Eric Meissner

List of Studies


Profiles_link
Keywords
Coronavirus, COVID-19, Healthy Volunteer Studies, Infectious Diseases, SARS-CoV-2
Summary

The purpose of this study is to estimate the extent to which health care workers at MUSC who may have higher than average risk for exposure to the novel coronavirus SARS-CoV-2, which causes an illness referred to as COVID-19, may have developed immunity to infection. Two groups of people will be asked to participate in this study. The first group is comprised of health care workers with a potentially higher risk of exposure who may have provided direct care or services for persons with SARS-CoV-2 infection as part of their work duties. The second group is comprised of employees whose job duties do not involve direct contact with patients. The purpose of the research is to determine if a certain marker in blood, IgG to SARS-CoV-2, can tell if participants may have been exposed to and now recovered from SARS-CoV-2 infection and how seroprevalence changes over time during the current outbreak in this population of study subjects.

Institution
MUSC
Recruitment Contact
Lauren Card
843-729-4394
cardl@musc.edu

Change_preferences

-- OR --

Create_login